Mustafa Khasraw

Overview:

I am a medical oncologist, neuro-oncologist, tenured professor of medicine and neurooncology, and Deputy Director of the Center for Cancer Immunotherapy, Duke Cancer Institute, where we are tasked to speed up clinical research and translation for scientists across all departments and all tumor types at Duke, who have made discoveries that show promise for developing new immunotherapies.

I am leading clinical and translational programs with laboratory collaborations with an interest in innovative trials designed to improve the outcome of patients with cancers of the CNS. 

I serve as an advisor and grant reviewer for several non-profits and patient advocacy groups. I am a Fellow of the Royal Australasian College of Physicians and an Elected Fellow of the Royal College of Physicians (UK). 

Positions:

Professor of Neurosurgery

Neurosurgery
School of Medicine

Professor in Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2001

Rijksuniversiteit Groningen (The Netherlands)

Grants:

Astellas 1951-CL-0101

Administered By
Duke Cancer Institute
Awarded By
Astellas Pharma Global Development, Inc
Role
Principal Investigator
Start Date
End Date

Celldex CDX-527

Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiform (WHO Grade IV) After Failure of Standard First Line

Administered By
Duke Cancer Institute
Awarded By
CNS Pharmaceuticals, Inc
Role
Principal Investigator
Start Date
End Date

Phase 1 BNT152+153 in patients with solid tumors

Administered By
Duke Cancer Institute
Awarded By
BioNTech SE
Role
Principal Investigator
Start Date
End Date

PARAMETer: A window of opportunity study of Patritumab Deruxtecan in patients with brain metastases

Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Role
Principal Investigator
Start Date
End Date

Publications:

Intra-aortic metastases or intra-arterial thrombus?

Authors
Lomax, AJ; Yap, SY; Khasraw, M
MLA Citation
Lomax, Anna J., et al. “Intra-aortic metastases or intra-arterial thrombus?International Journal of Case Reports and Images, vol. 4, no. 7, Edorium Journals Pvt. Ltd., 2013, pp. 368–368. Crossref, doi:10.5348/ijcri-2013-07-333-7.
URI
https://scholars.duke.edu/individual/pub1430997
Source
crossref
Published In
International Journal of Case Reports and Images
Volume
4
Published Date
Start Page
368
End Page
368
DOI
10.5348/ijcri-2013-07-333-7

Anti-angiogenic therapy for lung cancer

Authors
Pavlakis, N; Marx, G; White, S; Lee, CW; Khasraw, M
MLA Citation
Pavlakis, Nick, et al. “Anti-angiogenic therapy for lung cancer.” Cochrane Database of Systematic Reviews, Wiley, Oct. 2009. Crossref, doi:10.1002/14651858.cd008047.
URI
https://scholars.duke.edu/individual/pub1430991
Source
crossref
Published In
Cochrane Database of Systematic Reviews
Published Date
DOI
10.1002/14651858.cd008047

Management of glioblastoma: an Australian perspective.

Authors
Sim, H-W; Nowak, AK; Lwin, Z; Khasraw, M
MLA Citation
Sim, Hao-Wen, et al. “Management of glioblastoma: an Australian perspective.Chin Clin Oncol, vol. 10, no. 4, Aug. 2021, p. 42. Pubmed, doi:10.21037/cco.2020.02.05.
URI
https://scholars.duke.edu/individual/pub1432986
PMID
32075395
Source
pubmed
Published In
Chin Clin Oncol
Volume
10
Published Date
Start Page
42
DOI
10.21037/cco.2020.02.05

Patterns of care in adult histone mutant gliomas: Results of an international survey.

BACKGROUND: Histone mutant gliomas (HMG) with histone H3 K27 and G34 mutations are recognized as biologically discrete entities with distinct anatomical locations, younger age at presentation (in comparison to the most common high-grade gliomas, IDH wildtype glioblastoma), and poor prognosis. There is a paucity of data regarding the management of adult HMG patients and no consensus on management. This study aims to identify current patterns of Australian and US neuro-oncology clinical practice for this entity. METHODS: Following institutional approvals, patterns of care questionnaire designed to capture relevant clinical variables was circulated through the Cooperative Trials Group for Neuro-Oncology (COGNO) in Australia and the Caris Precision Oncology Alliance in the United States (US). RESULTS: Between 4/2021 and 10/2021, 43 responses were collected. 33% (n = 14) of responders tested all patients for HMGs routinely; 40.92% (n = 18) tested in select patients 26% (n = 11) did not test for HMGs. The common indications for testing selected patients were midline anatomic location (n = 18) and age (n = 11) (<50 years). 23 used molecular sequencing, 22 used IHC at their centers. Nine participants stated knowledge of histone H3 mutations did not affect their management of these gliomas, 11 said it affected their management at the time of recurrence, 23 stated it affected the management of midline K27M patients, 11 participants stated it affected the management of K27M mutant gliomas in other locations, and 3 felt it affected the management of G34R/V mutant gliomas. CONCLUSION: Here we present a description of how the discovery of a new molecular subtype of primary glial tumors, histone mutated gliomas in adults, is being introduced into clinical practice.
Authors
Yuile, A; Khasraw, M; Low, JT; Walsh, KM; Lipp, E; Sy, J; Satgunaseelan, L; Kastelan, MA; De Silva, M; Lee, A; Wheeler, H
MLA Citation
Yuile, Alexander, et al. “Patterns of care in adult histone mutant gliomas: Results of an international survey.Neurooncol Pract, vol. 9, no. 6, Dec. 2022, pp. 520–25. Pubmed, doi:10.1093/nop/npac047.
URI
https://scholars.duke.edu/individual/pub1550357
PMID
36388418
Source
pubmed
Published In
Neuro Oncology Practice
Volume
9
Published Date
Start Page
520
End Page
525
DOI
10.1093/nop/npac047

EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms.

Neuroendocrine neoplasms (NENs) are relatively rare neoplasms occurring predominantly in the gastrointestinal tract and pancreas. Their heterogeneity poses challenges for diagnosis and treatment. There is a paucity of markers for characterisation of NEN tumours. For routine diagnosis, immunohistochemistry of the NEN-specific markers CgA and synaptophysin and the proliferation marker Ki-67 are used. These parameters, however, are qualitative and lack the capacity to fully define the tumour phenotype. Molecules of epithelial-mesenchymal transition (EMT) are potential candidates for improved tumour characterisation. Using qRT-PCR, we measured mRNA levels of 27 tumour markers, including 25 EMT-associated markers, in tumour tissue and matched non-tumour tissues for 13 patients with pancreatic NENs. Tissue from patients with three different grades of tumour had distinctly different mRNA profiles. Of the 25 EMT-associated markers analysed, 17 were higher in G3 tissue relative to matched non-tumour tissue, including CD14, CD24, CD31, CD44, CD45, CD56, CK6, CK7, CK13, CK20, NSE, CDX2, CgA, DAXX, PCNA, laminin and Ki-67. The differences in levels of seven EMT-associated markers, Ki-67, DAXX, CD24, CD44, vimentin, laminin and PDX1 plus CgA and NSE (neuroendocrine markers) enabled a distinct molecular signature for each tumour grade to be generated. EMT molecules differentially expressed in three tumour grades have potential for use in tumour stratification and prognostication and as therapeutic targets for treatment of neuroendocrine cancers, following validation with additional samples.
Authors
Venugopal, A; Michalczyk, A; Khasraw, M; Ackland, ML
MLA Citation
Venugopal, Abhirami, et al. “EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms.Int J Mol Sci, vol. 23, no. 21, Nov. 2022. Pubmed, doi:10.3390/ijms232113645.
URI
https://scholars.duke.edu/individual/pub1556562
PMID
36362433
Source
pubmed
Published In
International Journal of Molecular Sciences
Volume
23
Published Date
DOI
10.3390/ijms232113645

Research Areas:

Anti-cancer
Cancer
Cancer Therapy Resistance
Cancer Vaccines
Cancer genes
Cancer--Immunotherapy
Drug development
Immunotherapy